Back to Results
First PageMeta Content
Pharmaceutical sciences / European Medicines Agency / Peginterferon alfa-2a / Interferon / Committee for Medicinal Products for Human Use / Peginterferon alfa-2b / Pharmacovigilance / Ribavirin / Hepatitis B / Antivirals / Pharmacology / Medicine


The role of EMA and drug approvals for chronic HBV/HCV Summit Conference Hepatitis B and C Brussels, 14-15 October[removed]Marco Cavaleri
Add to Reading List

Document Date: 2014-04-30 06:48:45


Open Document

File Size: 507,63 KB

Share Result on Facebook

Company

Safety&Efficacy Sector / Paediatrics Group / /

Continent

Europe / /

IndustryTerm

pharmaceuticals / healthcare professionals / medicinal products / TREATMENT FOR ALL VIRAL DISEASES / /

MedicalCondition

CHC / chronic HBV/HCV Summit Conference Hepatitis B / /

Organization

Committee for Paediatrics / European Union / Secretariat Committee for Orphan Medicinal Products / Committee for Advanced Therapies / European Medicines Agency / Committee for Herbal Medicinal Products / Committee for Human Medicinal Products / EMA Committee for Veterinary Medicinal Products / /

Position

Marco Cavaleri Head / /

Product

Pegasys / Hepsera / Rebetol / lamivudine / PegIntron / Viread / peginterferon / Copegus / ribavirin / Baraclude / /

ProgrammingLanguage

EC / /

Technology

CAT / /

SocialTag